Synthetic lethality: General principles, utility and detection using genetic screens in human cells

Bridges, 1922, The origin of variation, Amer Nat, 56, 51, 10.1086/279847 Dobzhansky, 1946, Genetics of natural populations. XIII. Recombination and variability in populations of Drosphila pseudoobscura, Genetics, 31, 269, 10.1093/genetics/31.3.269 Boone, 2007, Exploring genetic interactions and networks with yeast, Nat Rev Genet, 8, 437, 10.1038/nrg2085 Hartman, 2001, Principles for the buffering of genetic variation, Science, 291, 1001, 10.1126/science.291.5506.1001 Kaelin, 2005, The concept of synthetic lethality in the context of anticancer therapy, Nat Rev Cancer, 5, 689, 10.1038/nrc1691 Lehar, 2008, Combination chemical genetics, Nat Chem Biol, 4, 674, 10.1038/nchembio.120 Luo, 2009, Principles of cancer therapy: oncogene and non-oncogene addiction, Cell, 136, 823, 10.1016/j.cell.2009.02.024 Hillenmeyer, 2008, The chemical genomic portrait of yeast: uncovering a phenotype for all genes, Science, 320, 362, 10.1126/science.1150021 Dixon, 2009, Systematic mapping of genetic interaction networks, Annu Rev Genet, 43, 601, 10.1146/annurev.genet.39.073003.114751 Kaelin, 2009, Synthetic lethality: a framework for the development of wiser cancer therapeutics, Genome Med, 1, 99, 10.1186/gm99 Masel, 2009, Robustness: mechanisms and consequences, Trends Genet, 25, 395, 10.1016/j.tig.2009.07.005 Gibson, 2009, Decanalization and the origin of complex disease, Nat Rev Genet, 10, 134, 10.1038/nrg2502 Kirschner, 1998, Evolvability, Proc Natl Acad Sci U S A, 95, 8420, 10.1073/pnas.95.15.8420 Winzeler, 1999, Functional characterization of the S, Cerevisiae genome by gene deletion and parallel analysis. Science, 285, 901 Costanzo, 2010, The genetic landscape of a cell, Science, 327, 425, 10.1126/science.1180823 Whitehurst, 2007, Synthetic lethal screen identification of chemosensitizer loci in cancer cells, Nature, 446, 815, 10.1038/nature05697 Rutherford, 1998, Hsp90 as a capacitor for morphological evolution, Nature, 396, 336, 10.1038/24550 Lehner, 2006, Systematic mapping of genetic interactions in Caenorhabditis elegans identifies common modifiers of diverse signaling pathways, Nat Genet, 38, 896, 10.1038/ng1844 Whitesell, 2005, HSP90 and the chaperoning of cancer, Nat Rev Cancer, 5, 761, 10.1038/nrc1716 Fiedler, 2009, Functional organization of the S. cerevisiae phosphorylation network, Cell, 136, 952, 10.1016/j.cell.2008.12.039 Lum, 2004, Discovering modes of action for therapeutic compounds using a genome-wide screen of yeast heterozygotes, Cell, 116, 121, 10.1016/S0092-8674(03)01035-3 St Onge, 2007, Systematic pathway analysis using high-resolution fitness profiling of combinatorial gene deletions, Nat Genet, 39, 199, 10.1038/ng1948 Yu, 2008, Chemical-genetic profiling of imidazo[1, 2-a]pyridines and -pyrimidines reveals target pathways conserved between yeast and human cells, PLoS Genet, 4, e1000284, 10.1371/journal.pgen.1000284 Ericson, 2008, Off-target effects of psychoactive drugs revealed by genome-wide assays in yeast, PLoS Genet, 4, e1000151, 10.1371/journal.pgen.1000151 Guo, 2008, Identification of a small molecule with synthetic lethality for K-ras and protein kinase C iota, Cancer Res, 68, 7403, 10.1158/0008-5472.CAN-08-1449 Turcotte, 2008, A molecule targeting VHL-deficient renal cell carcinoma that induces autophagy, Cancer Cell, 14, 90, 10.1016/j.ccr.2008.06.004 Dolma, 2003, Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells, Cancer Cell, 3, 285, 10.1016/S1535-6108(03)00050-3 Turner, 2008, A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor, EMBO J, 27, 1368, 10.1038/emboj.2008.61 Zimmermann, 2007, Multi-target therapeutics: when the whole is greater than the sum of the parts, Drug Discov Today, 12, 34, 10.1016/j.drudis.2006.11.008 Hartwell, 1997, Integrating genetic approaches into the discovery of anticancer drugs, Science, 278, 1064, 10.1126/science.278.5340.1064 Weinstein, 2002, Cancer. Addiction to oncogenes–the Achilles heal of cancer, Science, 297, 63, 10.1126/science.1073096 Farmer, 2005, Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy, Nature, 434, 917, 10.1038/nature03445 Bryant, 2005, Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase, Nature, 434, 913, 10.1038/nature03443 Fong, 2009, Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers, N Engl J Med, 361, 123, 10.1056/NEJMoa0900212 Fong, 2010, Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval, J Clin Oncol, 28, 2512, 10.1200/JCO.2009.26.9589 Wiltshire, 2010, Sensitivity to poly(ADP-ribose) polymerase (PARP) inhibition identifies ubiquitin-specific peptidase 11 (USP11) as a regulator of DNA double-strand break repair, J Biol Chem, 285, 14565, 10.1074/jbc.M110.104745 Mendes-Pereira, 2009, Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors, EMBO Mol Med, 1, 315, 10.1002/emmm.200900041 Orsburn, 2010, Differential requirement for H2AX and 53BP1 in organismal development and genome maintenance in the absence of poly(ADP)ribosyl polymerase 1, Mol Cell Biol, 30, 2341, 10.1128/MCB.00091-10 Sandhu, 2010, Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective, Eur J Cancer, 46, 9, 10.1016/j.ejca.2009.10.021 Ashworth, 2008, A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair, J Clin Oncol, 26, 3785, 10.1200/JCO.2008.16.0812 Iglehart, 2009, Synthetic lethality–a new direction in cancer-drug development, N Engl J Med, 361, 189, 10.1056/NEJMe0903044 Wong, 2004, Combining biological networks to predict genetic interactions, Proc Natl Acad Sci U S A, 101, 15682, 10.1073/pnas.0406614101 Roguev, 2008, Conservation and rewiring of functional modules revealed by an epistasis map in fission yeast, Science, 322, 405, 10.1126/science.1162609 Dixon, 2008, Significant conservation of synthetic lethal genetic interaction networks between distantly related eukaryotes, Proc Natl Acad Sci U S A, 105, 16653, 10.1073/pnas.0806261105 Tarailo, 2007, Synthetic lethal interactions identify phenotypic “interologs” of the spindle assembly checkpoint components, Genetics, 177, 2525, 10.1534/genetics.107.080408 Tischler, 2008, Evolutionary plasticity of genetic interaction networks, Nat Genet, 40, 390, 10.1038/ng.114 Byrne, 2007, A global analysis of genetic interactions in Caenorhabditis elegans, J Biol, 6, 8, 10.1186/jbiol58 McManus, 2009, Specific synthetic lethal killing of RAD54B-deficient human colorectal cancer cells by FEN1 silencing, Proc Natl Acad Sci U S A, 106, 3276, 10.1073/pnas.0813414106 Conde-Pueyo, 2009, Human synthetic lethal inference as potential anti-cancer target gene detection, BMC Syst Biol, 3, 116, 10.1186/1752-0509-3-116 McLellan, 2009, Synthetic lethal genetic interactions that decrease somatic cell proliferation in Caenorhabditis elegans identify the alternative RFC CTF18 as a candidate cancer drug target, Mol Biol Cell, 20, 5306, 10.1091/mbc.e09-08-0699 Torrance, 2001, Use of isogenic human cancer cells for high-throughput screening and drug discovery, Nat Biotechnol, 19, 940, 10.1038/nbt1001-940 Shoemaker, 2006, The NCI60 human tumour cell line anticancer drug screen, Nat Rev Cancer, 6, 813, 10.1038/nrc1951 Ngo, 2006, A loss-of-function RNA interference screen for molecular targets in cancer, Nature, 441, 106, 10.1038/nature04687 Schlabach, 2008, Cancer proliferation gene discovery through functional genomics, Science, 319, 620, 10.1126/science.1149200 Silva, 2008, Profiling essential genes in human mammary cells by multiplex RNAi screening, Science, 319, 617, 10.1126/science.1149185 Luo, 2008, Highly parallel identification of essential genes in cancer cells, Proc Natl Acad Sci U S A, 105, 20380, 10.1073/pnas.0810485105 Scholl, 2009, Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells, Cell, 137, 821, 10.1016/j.cell.2009.03.017 Barbie, 2009, Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1, Nature, 462, 108, 10.1038/nature08460 Mayo, 1997, Requirement of NF-kappaB activation to suppress p53-independent apoptosis induced by oncogenic Ras, Science, 278, 1812, 10.1126/science.278.5344.1812 Chien, 2006, RalB GTPase-mediated activation of the IkappaB family kinase TBK1 couples innate immune signaling to tumor cell survival, Cell, 127, 157, 10.1016/j.cell.2006.08.034 Meylan, 2009, Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma, Nature, 462, 104, 10.1038/nature08462 Luo, 2009, A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene, Cell, 137, 835, 10.1016/j.cell.2009.05.006 Wang, 2010, Critical role for transcriptional repressor Snail2 in transformation by oncogenic RAS in colorectal carcinoma cells, Oncogene, 29, 4658, 10.1038/onc.2010.218 Carette, 2009, Haploid genetic screens in human cells identify host factors used by pathogens, Science, 326, 1231, 10.1126/science.1178955